| MeSH term | MeSH ID | Detail |
|---|---|---|
| Diabetes Mellitus, Type 2 | D003924 | 87 associated lipids |
| Diabetic Retinopathy | D003930 | 39 associated lipids |
| Fatty Liver | D005234 | 48 associated lipids |
| Diabetes Mellitus, Experimental | D003921 | 85 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
| Edema | D004487 | 152 associated lipids |
| Arthritis, Experimental | D001169 | 24 associated lipids |
| Hypotension | D007022 | 41 associated lipids |
| Prostatic Neoplasms | D011471 | 126 associated lipids |
| Melanoma | D008545 | 69 associated lipids |
Anandamide
Anandamide is a lipid of Fatty Acyls (FA) class. Anandamide is associated with abnormalities such as Dehydration. The involved functions are known as Process, Phenomenon, Phosphorylation, Catabolic Process and Gene Expression. Anandamide often locates in Nuchal region, Microglial and Hepatic. The associated genes with Anandamide are SGPL1 gene, SPTLC1 gene, RPSA gene, KDSR gene and SMPD1 gene. The related lipids are Sphingolipids, Lipopolysaccharides, Lysophospholipids, LYSO-PC and lysophosphatidylethanolamine.
Cross Reference
Introduction
To understand associated biological information of Anandamide, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with Anandamide?
Anandamide is suspected in Dehydration and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with Anandamide
PubChem Associated disorders and diseases
What pathways are associated with Anandamide
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with Anandamide?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with Anandamide?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with Anandamide?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with Anandamide?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with Anandamide?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with Anandamide
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Murillo-RodrÃguez E et al. | Cannabidiol, a constituent of Cannabis sativa, modulates sleep in rats. | 2006 | FEBS Lett. | pmid:16844117 |
| Schmid PC et al. | Occurrence and postmortem generation of anandamide and other long-chain N-acylethanolamines in mammalian brain. | 1995 | FEBS Lett. | pmid:7498458 |
| Sarker KP et al. | Anandamide induces apoptosis of PC-12 cells: involvement of superoxide and caspase-3. | 2000 | FEBS Lett. | pmid:10781801 |
| Wang Y et al. | Polymyxin B binds to anandamide and inhibits its cytotoxic effect. | 2000 | FEBS Lett. | pmid:10734225 |
| Di Marzo V et al. | Interactions between synthetic vanilloids and the endogenous cannabinoid system. | 1998 | FEBS Lett. | pmid:9801167 |
| Fowler CJ | Transport of endocannabinoids across the plasma membrane and within the cell. | 2013 | FEBS J. | pmid:23441874 |
| Stark K et al. | Expression and purification of orphan cytochrome P450 4X1 and oxidation of anandamide. | 2008 | FEBS J. | pmid:18549450 |
| van der Stelt M et al. | A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease. | 2005 | FASEB J. | pmid:15894565 |
| Mascolo N et al. | The endocannabinoid system and the molecular basis of paralytic ileus in mice. | 2002 | FASEB J. | pmid:12397089 |
| Varga K et al. | Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. | 1998 | FASEB J. | pmid:9707176 |
| Bátkai S et al. | Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury. | 2007 | FASEB J. | pmid:17327359 |
| Karwad MA et al. | The role of CB in intestinal permeability and inflammation. | 2017 | FASEB J. | pmid:28404744 |
| Baker D et al. | Endocannabinoids control spasticity in a multiple sclerosis model. | 2001 | FASEB J. | pmid:11156943 |
| D'Argenio G et al. | Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. | 2006 | FASEB J. | pmid:16403786 |
| Bifulco M et al. | Control by the endogenous cannabinoid system of ras oncogene-dependent tumor growth. | 2001 | FASEB J. | pmid:11687506 |
| Di Marzo V et al. | Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. | 2000 | FASEB J. | pmid:10877836 |
| Berdyshev EV et al. | Activation of PAF receptors results in enhanced synthesis of 2-arachidonoylglycerol (2-AG) in immune cells. | 2001 | FASEB J. | pmid:11641243 |
| Jones S and Howl J | Cannabinoid receptor systems: therapeutic targets for tumour intervention. | 2003 | Expert Opin. Ther. Targets | pmid:14640910 |
| Lory P and Chemin J | Towards the discovery of novel T-type calcium channel blockers. | 2007 | Expert Opin. Ther. Targets | pmid:17465728 |
| Bambico FR and Gobbi G | The cannabinoid CB1 receptor and the endocannabinoid anandamide: possible antidepressant targets. | 2008 | Expert Opin. Ther. Targets | pmid:18851692 |
| Wise ML et al. | Synthesis and cannabinoid receptor binding activity of conjugated triene anandamide, a novel eicosanoid. | 1996 | Experientia | pmid:8575565 |
| Feizi A et al. | The preventive effect of cannabinoids on reperfusion-induced ischemia of mouse kidney. | 2008 | Exp. Toxicol. Pathol. | pmid:18571910 |
| Venderova K et al. | Differential effects of endocannabinoids on [(3)H]-GABA uptake in the rat globus pallidus. | 2005 | Exp. Neurol. | pmid:15899265 |
| Hansen HS | Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain. | 2010 | Exp. Neurol. | pmid:20353771 |
| Greco R et al. | The endocannabinoid system and migraine. | 2010 | Exp. Neurol. | pmid:20353780 |
| Bhaskaran MD and Smith BN | Effects of TRPV1 activation on synaptic excitation in the dentate gyrus of a mouse model of temporal lobe epilepsy. | 2010 | Exp. Neurol. | pmid:20144892 |
| Kreutz S et al. | Cannabinoids and neuronal damage: differential effects of THC, AEA and 2-AG on activated microglial cells and degenerating neurons in excitotoxically lesioned rat organotypic hippocampal slice cultures. | 2007 | Exp. Neurol. | pmid:17010339 |
| Bir LS and Ercan S | Effects of intrathecal anandamide on somatosensory evoked responses in rats. | 2006 | Exp. Neurol. | pmid:16289169 |
| Solbrig MV et al. | A role for endocannabinoids in viral-induced dyskinetic and convulsive phenomena. | 2005 | Exp. Neurol. | pmid:16022863 |
| Morgese MG et al. | Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors. | 2007 | Exp. Neurol. | pmid:17900568 |
| Köse S et al. | Human bone marrow mesenchymal stem cells secrete endocannabinoids that stimulate in vitro hematopoietic stem cell migration effectively comparable to beta-adrenergic stimulation. | 2018 | Exp. Hematol. | pmid:29030083 |
| Matsuda S et al. | Metabolism of anandamide, an endogenous cannabinoid receptor ligand, in porcine ocular tissues. | 1997 | Exp. Eye Res. | pmid:9245900 |
| Jumpertz R et al. | Circulating endocannabinoids and N-acyl-ethanolamides in patients with sleep apnea--specific role of oleoylethanolamide. | 2010 | Exp. Clin. Endocrinol. Diabetes | pmid:20429051 |
| De Petrocellis L et al. | Regulation of transient receptor potential channels of melastatin type 8 (TRPM8): effect of cAMP, cannabinoid CB(1) receptors and endovanilloids. | 2007 | Exp. Cell Res. | pmid:17428469 |
| Frampton G et al. | Opposing actions of endocannabinoids on cholangiocarcinoma growth is via the differential activation of Notch signaling. | 2010 | Exp. Cell Res. | pmid:20347808 |
| Grimaldi C et al. | Anandamide inhibits adhesion and migration of breast cancer cells. | 2006 | Exp. Cell Res. | pmid:16343481 |
| Prestifilippo JP et al. | Inhibition of salivary secretion by activation of cannabinoid receptors. | 2006 | Exp. Biol. Med. (Maywood) | pmid:16946411 |
| Wiley JL et al. | A comparison of the discriminative stimulus effects of delta(9)-tetrahydrocannabinol and O-1812, a potent and metabolically stable anandamide analog, in rats. | 2004 | Exp Clin Psychopharmacol | pmid:15301634 |
| Burkey RT and Nation JR | (R)-methanandamide, but not anandamide, substitutes for delta 9-THC in a drug-discrimination procedure. | 1997 | Exp Clin Psychopharmacol | pmid:9260067 |
| Gratzke C et al. | Localization and function of cannabinoid receptors in the corpus cavernosum: basis for modulation of nitric oxide synthase nerve activity. | 2010 | Eur. Urol. | pmid:19147270 |
| Prieto D | Editorial comment on: localization and function of cannabinoid receptors in the corpus cavernosum: basis for modulation of nitric oxide synthase nerve activity. | 2010 | Eur. Urol. | pmid:19147273 |
| Wheal AJ and Randall MD | Effects of hypertension on vasorelaxation to endocannabinoids in vitro. | 2009 | Eur. J. Pharmacol. | pmid:19100733 |
| Chen N et al. | Inhibition by arachidonic acid and other fatty acids of dopamine uptake at the human dopamine transporter. | 2003 | Eur. J. Pharmacol. | pmid:14575792 |
| Beltramo M and Piomelli D | Anandamide transport inhibition by the vanilloid agonist olvanil. | 1999 | Eur. J. Pharmacol. | pmid:9920187 |
| Stengel PW et al. | Pulmonary actions of anandamide, an endogenous cannabinoid receptor agonist, in guinea pigs. | 1998 | Eur. J. Pharmacol. | pmid:9754939 |
| Wallace MJ et al. | Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity. | 2002 | Eur. J. Pharmacol. | pmid:12359270 |
| Kelley BG and Thayer SA | Anandamide transport inhibitor AM404 and structurally related compounds inhibit synaptic transmission between rat hippocampal neurons in culture independent of cannabinoid CB1 receptors. | 2004 | Eur. J. Pharmacol. | pmid:15288572 |
| O'Sullivan SE et al. | Vascular effects of delta 9-tetrahydrocannabinol (THC), anandamide and N-arachidonoyldopamine (NADA) in the rat isolated aorta. | 2005 | Eur. J. Pharmacol. | pmid:15659311 |
| Saitoh C et al. | The differential contractile responses to capsaicin and anandamide in muscle strips isolated from the rat urinary bladder. | 2007 | Eur. J. Pharmacol. | pmid:17586490 |
| Wagner JA et al. | Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors. | 2001 | Eur. J. Pharmacol. | pmid:11448486 |
| Orliac ML et al. | Increases in vanilloid TRPV1 receptor protein and CGRP content during endotoxemia in rats. | 2007 | Eur. J. Pharmacol. | pmid:17482593 |
| Wheal AJ et al. | Hydrogen peroxide as a mediator of vasorelaxation evoked by N-oleoylethanolamine and anandamide in rat small mesenteric arteries. | 2012 | Eur. J. Pharmacol. | pmid:22154756 |
| McQueen DS et al. | Cannabidiol lacks the vanilloid VR1-mediated vasorespiratory effects of capsaicin and anandamide in anaesthetised rats. | 2004 | Eur. J. Pharmacol. | pmid:15140635 |
| Fowler CJ et al. | Selective inhibition of anandamide cellular uptake versus enzymatic hydrolysis--a difficult issue to handle. | 2004 | Eur. J. Pharmacol. | pmid:15145699 |
| Romano MR and Lograno MD | Involvement of the peroxisome proliferator-activated receptor (PPAR) alpha in vascular response of endocannabinoids in the bovine ophthalmic artery. | 2012 | Eur. J. Pharmacol. | pmid:22429572 |
| Wiley JL et al. | Endocannabinoid contribution to Δ9-tetrahydrocannabinol discrimination in rodents. | 2014 | Eur. J. Pharmacol. | pmid:24858366 |
| Mendizábal VE et al. | Long-term inhibition of nitric oxide synthase potentiates effects of anandamide in the rat mesenteric bed. | 2001 | Eur. J. Pharmacol. | pmid:11567656 |
| Bermúdez-Siva FJ et al. | Activation of cannabinoid CB1 receptors induces glucose intolerance in rats. | 2006 | Eur. J. Pharmacol. | pmid:16423347 |
| Shimasue K et al. | Effects of anandamide and arachidonic acid on specific binding of (+) -PN200-110, diltiazem and (-) -desmethoxyverapamil to L-type Ca2+ channel. | 1996 | Eur. J. Pharmacol. | pmid:8904088 |
| Basavarajappa BS et al. | Chronic ethanol inhibits the anandamide transport and increases extracellular anandamide levels in cerebellar granule neurons. | 2003 | Eur. J. Pharmacol. | pmid:12679143 |
| Wiley J et al. | Discriminative stimulus effects of anandamide in rats. | 1995 | Eur. J. Pharmacol. | pmid:7781695 |
| Guindon J et al. | Synergistic antinociceptive effects of anandamide, an endocannabinoid, and nonsteroidal anti-inflammatory drugs in peripheral tissue: a role for endogenous fatty-acid ethanolamides? | 2006 | Eur. J. Pharmacol. | pmid:17027744 |
| Pelorosso FG et al. | The endocannabinoid anandamide inhibits kinin B1 receptor sensitization through cannabinoid CB1 receptor stimulation in human umbilical vein. | 2009 | Eur. J. Pharmacol. | pmid:19022239 |
| Walentiny DM et al. | The endogenous cannabinoid anandamide shares discriminative stimulus effects with ∆(9)-tetrahydrocannabinol in fatty acid amide hydrolase knockout mice. | 2011 | Eur. J. Pharmacol. | pmid:21300050 |
| GarcÃa Mdel C et al. | Impaired hypotensive responses induced by intrathecally injected drugs in fructose-fed rats. | 2013 | Eur. J. Pharmacol. | pmid:23499700 |
| Peroni RN et al. | Participation of CGRP and prostanoids in the sex-linked differences of vascular anandamide effects in mesenteric beds of Sprague-Dawley rats. | 2007 | Eur. J. Pharmacol. | pmid:17169358 |
| Smid SD et al. | The endocannabinoids anandamide and 2-arachidonoylglycerol inhibit cholinergic contractility in the human colon. | 2007 | Eur. J. Pharmacol. | pmid:17706636 |
| Mechoulam R et al. | Endocannabinoids. | 1998 | Eur. J. Pharmacol. | pmid:9831287 |
| Russo R et al. | Synergistic antinociception by the cannabinoid receptor agonist anandamide and the PPAR-alpha receptor agonist GW7647. | 2007 | Eur. J. Pharmacol. | pmid:17434479 |
| Barg J et al. | Cannabinomimetic behavioral effects of and adenylate cyclase inhibition by two new endogenous anandamides. | 1995 | Eur. J. Pharmacol. | pmid:8749028 |
| Ghasemi M et al. | Effect of anandamide on nonadrenergic noncholinergic-mediated relaxation of rat corpus cavernosum. | 2006 | Eur. J. Pharmacol. | pmid:16824514 |
| Gifford AN et al. | Potentiation of the action of anandamide on hippocampal slices by the fatty acid amide hydrolase inhibitor, palmitylsulphonyl fluoride (AM 374). | 1999 | Eur. J. Pharmacol. | pmid:10556675 |
| Wiley JL et al. | Task specificity of cross-tolerance between Delta9-tetrahydrocannabinol and anandamide analogs in mice. | 2005 | Eur. J. Pharmacol. | pmid:15740725 |
| Zaniewska M et al. | Evaluation of the role of nicotinic acetylcholine receptor subtypes and cannabinoid system in the discriminative stimulus effects of nicotine in rats. | 2006 | Eur. J. Pharmacol. | pmid:16730696 |
| Varga K et al. | Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide. | 1995 | Eur. J. Pharmacol. | pmid:7589169 |
| Randall MD et al. | Comparative pharmacology of endothelium-derived hyperpolarizing factor and anandamide in rat isolated mesentery. | 1997 | Eur. J. Pharmacol. | pmid:9314035 |
| Hao S et al. | Low dose anandamide affects food intake, cognitive function, neurotransmitter and corticosterone levels in diet-restricted mice. | 2000 | Eur. J. Pharmacol. | pmid:10762668 |
| Randall MD and Kendall DA | Involvement of a cannabinoid in endothelium-derived hyperpolarizing factor-mediated coronary vasorelaxation. | 1997 | Eur. J. Pharmacol. | pmid:9369375 |
| Mukherjee S et al. | Species comparison and pharmacological characterization of rat and human CB2 cannabinoid receptors. | 2004 | Eur. J. Pharmacol. | pmid:15556131 |
| Burkey TH et al. | Relative efficacies of cannabinoid CB1 receptor agonists in the mouse brain. | 1997 | Eur. J. Pharmacol. | pmid:9384246 |
| López-Miranda V et al. | Anandamide vehicles: a comparative study. | 2004 | Eur. J. Pharmacol. | pmid:15556148 |
| Braida D et al. | 5-HT1A receptors are involved in the anxiolytic effect of Delta9-tetrahydrocannabinol and AM 404, the anandamide transport inhibitor, in Sprague-Dawley rats. | 2007 | Eur. J. Pharmacol. | pmid:17116299 |
| Castelli MP et al. | Dysregulation of the endogenous cannabinoid system in adult rats prenatally treated with the cannabinoid agonist WIN 55,212-2. | 2007 | Eur. J. Pharmacol. | pmid:17644084 |
| Marichal-Cancino BA et al. | Analysis of anandamide- and lysophosphatidylinositol-induced inhibition of the vasopressor responses produced by sympathetic stimulation or noradrenaline in pithed rats. | 2013 | Eur. J. Pharmacol. | pmid:24076186 |
| Wise LE et al. | Assessment of anandamide's pharmacological effects in mice deficient of both fatty acid amide hydrolase and cannabinoid CB1 receptors. | 2007 | Eur. J. Pharmacol. | pmid:17217945 |
| Adinolfi B et al. | Anticancer activity of anandamide in human cutaneous melanoma cells. | 2013 | Eur. J. Pharmacol. | pmid:24041928 |
| Oz M et al. | Endogenous cannabinoid anandamide directly inhibits voltage-dependent Ca(2+) fluxes in rabbit T-tubule membranes. | 2000 | Eur. J. Pharmacol. | pmid:10980258 |
| Smart D et al. | Characterisation using FLIPR of human vanilloid VR1 receptor pharmacology. | 2001 | Eur. J. Pharmacol. | pmid:11301059 |
| Kagota S et al. | 2-Arachidonoylglycerol, a candidate of endothelium-derived hyperpolarizing factor. | 2001 | Eur. J. Pharmacol. | pmid:11275004 |
| Dembiński A et al. | Dual, time-dependent deleterious and protective effect of anandamide on the course of cerulein-induced acute pancreatitis. Role of sensory nerves. | 2008 | Eur. J. Pharmacol. | pmid:18593574 |
| Kopczyńska B et al. | Anandamide enhances expression of heat shock proteins Hsp70 and Hsp25 in rat lungs. | 2011 | Eur. J. Pharmacol. | pmid:21756900 |
| Lisboa SF et al. | Activation of cannabinoid CB1 receptors in the dorsolateral periaqueductal gray induces anxiolytic effects in rats submitted to the Vogel conflict test. | 2008 | Eur. J. Pharmacol. | pmid:18691568 |
| Sordelli MS et al. | Cyclooxygenase-2 prostaglandins mediate anandamide-inhibitory action on nitric oxide synthase activity in the receptive rat uterus. | 2012 | Eur. J. Pharmacol. | pmid:22554772 |
| Ndong C et al. | Cloning and pharmacological characterization of the dog cannabinoid CBâ‚‚receptor. | 2011 | Eur. J. Pharmacol. | pmid:21871882 |
| Di Marzo V et al. | Neurobehavioral activity in mice of N-vanillyl-arachidonyl-amide. | 2000 | Eur. J. Pharmacol. | pmid:11040343 |
| Thors L and Fowler CJ | Effect of nitric oxide donors on membrane tritium accumulation of endocannabinoids and related endogenous lipids. | 2009 | Eur. J. Pharmacol. | pmid:19715690 |
| Calignano A et al. | Inhibition of intestinal motility by anandamide, an endogenous cannabinoid. | 1997 | Eur. J. Pharmacol. | pmid:9537804 |
| Richardson JD et al. | Antihyperalgesic effects of spinal cannabinoids. | 1998 | Eur. J. Pharmacol. | pmid:9600630 |
| Costa B et al. | Chronic treatment with the endocannabinoid anandamide increases cytochrome P450 metabolizing system in the rat. | 2002 | Eur. J. Pharmacol. | pmid:12163107 |
| de Lago E et al. | UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of anandamide. | 2002 | Eur. J. Pharmacol. | pmid:12163112 |